Pemetrexed disodium

Pemetrexed disodium
Product Name Pemetrexed disodium
CAS No.: 150399-23-8
Catalog No.: CFN90017
Molecular Formula: C20H19N5Na2O6
Molecular Weight: 471.37 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Targets: MEK | ERK
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price:
Pemetrexed disodium is a multitargeted antifolate cytotoxic agent mainly used in lung cancer, is an antimetabolite drug, that inhibits enzymes involved in nucleotides bio-synthesis arresting cancer cells cycle. Pemetrexed disodium activates MEK/ERK-dependent cyto-protective autophagy, and inhibition of this pathway potentiates Pemetrexed disodium's activity in HepG2 cells.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Aquaculture2017, 481:94-102
  • Biomolecules.2020, 10(6):925.
  • Trop J Nat Prod Res, February2023, 7(2):2371-2381
  • J Pain Res.2022, 15:3469-3478.
  • Int Immunopharmacol.2019, 71:22-31
  • Food Research2022, 6(6): 30-38.
  • Life (Basel).2022, 12(12):2107.
  • Plants (Basel).2021, 10(11):2525.
  • Front Microbiol.2022, 13:835463.
  • Molecules.2017, 22(3)
  • Tenofovir disoproxil

    Catalog No: CFN90016
    CAS No: 201341-05-1
    Price: Inquiry(manager@chemfaces.com)
    Pemetrexed disodium

    Catalog No: CFN90017
    CAS No: 150399-23-8
    Price: Inquiry(manager@chemfaces.com)
    Adenosine cyclophosphate

    Catalog No: CFN90031
    CAS No: 60-92-4
    Price: $40/20mg
    Thiamine hydrochloride

    Catalog No: CFN90068
    CAS No: 67-03-8
    Price: $30/20mg
    Expert Opin Investig Drugs. 2012 Apr;21(4):437-49.
    Pemetrexed disodium in ovarian cancer treatment.[Pubmed: 22324304]
    Current therapies for recurrent ovarian cancer (OC) yield relatively modest improvements in survival. Many drugs are available but recently a renewed interest is addressed on antimetabolite drugs. Pemetrexed disodium (PEM) is a multitargeted antifolate cytotoxic agent mainly used in lung cancer.
    METHODS AND RESULTS:
    This review summarizes the available evidence on the use of Pemetrexed disodium in the treatment of OC. This article consists of material obtained via Medline, PubMed and EMBASE literature searches, up to November 2011. Currently available published data on mechanism of action, pharmacokinetics, safety and efficacy of Pemetrexed disodium in the treatment of recurrent OC are described. EXPERT OPINION: Eight trials evaluated the use of Pemetrexed disodium in OC patients. Studies using Pemetrexed disodium in combination with carboplatin in platinum-sensitive OC suggested that the response rate is similar to other combination therapies. However, based on the absence of randomized trials comparing this doublet with currently used combination treatments, it is difficult to draw conclusions on the efficacy of Pemetrexed disodium regimens in these patients.
    CONCLUSIONS:
    In platinum-resistant OC patients, two studies suggested that Pemetrexed disodium alone might have equivalent activity to other single-agent treatment. Further pharmacogenomic and clinical data are warranted to better define the role of Pemetrexed disodium in the treatment of recurrent OC.
    Lung Cancer. 2015 Jun;88(3):319-24.
    Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.[Pubmed: 25870156 ]
    Pemetrexed disodium has been approved for the treatment of advanced non-small cell lung cancer (NSCLC) non-squamous histology, both as first- and second-line therapy. Pemetrexed disodium is an antimetabolite drug, that inhibits enzymes involved in nucleotides bio-synthesis arresting cancer cells cycle. The aim of this study was the evaluation of the impact of Pemetrexed disodium on erythrocyte mean corpuscular volume (MCV) change and its possible correlation with disease control rate (DCR), progression free (PFS) and overall survival (OS) in NSCLC patients.
    METHODS AND RESULTS:
    A retrospective collection of clinical and laboratory data (including basal MCV and maximum MCV occurred during therapy) in advanced NSCLC patients treated with Pemetrexed disodium at seven Italian centers was performed. Nonparametric tests, univariate and multivariate analysis were used to assess correlation between variables and to identify predictors of outcomes. 191 patients were enrolled: median age 62, 60% male, 61% performance status (PS) 0, 91% stage IV, 88% adenocarcinoma histotype, 25% never smoker, 62% received Pemetrexed disodium as first-line. Mean MCV significantly increased from basal (89fL) to during treatment (94fL), with mean ΔMCV=4fL. The median time from therapy start to maximum MCV was 2.2 months. Median PFS was 7 [CI95% 6-8] and 3 [CI95% 2-4] months [P=0.0016], and median survival was 17 [CI95% 12-23] and 10 [CI95% 8-12] months [P=0.02], in patients with ΔMCV>5fL (n=80) and ΔMCV≤5fL (n=111), respectively. Multivariate analysis identified age ≥62, PS 0, adenocarcinoma histology and ΔMCV>5fL as independent predictors of longer PFS. A ΔMCV>5fL significantly correlates with DCR.
    CONCLUSIONS:
    Pemetrexed disodium induces macrocytosis. ΔMCV>5fL on Pemetrexed disodium therapy correlated with better DCR, PFS and OS. These results deserve further validation in prospective studies.
    Biochem Biophys Res Commun. 2015 Jan 2;456(1):86-91.
    Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells.[Pubmed: 25446102 ]
    Identification of efficient chemo-therapeutic/chemo-preventive agents for treatment of hepatocellular carcinoma (HCC) is important.
    METHODS AND RESULTS:
    In this study, we examined the activity of pemetrexed, an anti-folate chemotherapy drug, against HepG2 human HCC cells. Pemetrexed disodium treatment in vitro exerted weak but significant cytotoxic activity against HepG2 cells. When analyzing the possible Pemetrexed disodium-resistance factors, we indentified that Pemetrexed disodium treatment in HepG2 cells induced cyto-protective autophagy activation, evidenced by GFP-light chain 3B (LC3B) puncta formation, p62 downregulation and Beclin-1/LC3B-II upregulation. Correspondingly, autophagy inhibitors, including bafliomycin A1, 3-methyladenine and chloroquine, enhanced Pemetrexed disodium-induced cytotoxicity against HepG2 cells. Further, RNAi-mediated knockdown of Beclin-1 in HepG2 cells also increased pemetrexed sensitivity. Pemetrexed disodium activated MEK (mitogen-activated protein kinase/ERK kinase)/ERK (extracellular-signal-regulated kinase) signaling in HepG2 cells, which was required for autophagy induction. Pharmacological inhibition of MEK/ERK activation attenuated Pemetrexed disodium-induced autophagy, enhanced HepG2 cell death and apoptosis.
    CONCLUSIONS:
    In summary, Pemetrexed disodium activates MEK/ERK-dependent cyto-protective autophagy, and inhibition of this pathway potentiates Pemetrexed disodium's activity in HepG2 cells.
    Molecules. 2015 May 29;20(6):10004-31.
    Synthesis and physicochemical characterization of the impurities of pemetrexed disodium, an anticancer drug.[Pubmed: 26035100]
    A physicochemical characterization of the process-related impurities associated with the synthesis of Pemetrexed disodium was performed. The possibility of pemetrexed impurities forming has been mentioned in literature, but no study on their structure has been published yet.
    METHODS AND RESULTS:
    This paper describes the development of the synthesis methods for these compounds and discusses their structure elucidation on the basis of two-dimensional NMR experiments and MS data. The identification of these impurities should be useful for the quality control during the production of the Pemetrexed disodium salt.
    7-Neohesperidosides

    Catalog No: CFN95018
    CAS No: 28383-41-7
    Price: $288/5mg
    Dihydrolicoisoflavone

    Catalog No: CFN95073
    CAS No: 164163-92-2
    Price: $333/5mg
    Isorubrofusarin 10-gentiobioside

    Catalog No: CFN95119
    CAS No: 200127-93-1
    Price: $338/10mg
    Momordicine V

    Catalog No: CFN95164
    CAS No: 1012315-36-4
    Price: $463/5mg
    Ginsenoside MC

    Catalog No: CFN95232
    CAS No: 175484-06-7
    Price: $318/10mg
    N1,N5,N10-(Z)-tri-p-coumaroylspermidine

    Catalog No: CFN95253
    CAS No: 131086-78-7
    Price: $238/5mg
    Ganolucidic acid D

    Catalog No: CFN95472
    CAS No: 102607-22-7
    Price: $413/5mg
    Kaempferol 3,5-O-diglucoside

    Catalog No: CFN95487
    CAS No: 205103-97-5
    Price: $318/10mg
    (R)-Mucronulatol

    Catalog No: CFN95492
    CAS No: 57128-11-7
    Price: $318/10mg
    beta-Hydroxyacteoside

    Catalog No: CFN95499
    CAS No: 109279-13-2
    Price: $318/10mg